Benjamin N. Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Benjamin N. Ma has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ronald Gust
Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria
3 shared publications - Sami El Deeb
Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, 38106 Braunschweig, Germany
3 shared publications Daniel Baecker
Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI-Center for Molecular Biosciences Innsbruck , University of Innsbruck, CCB-Center for Chemistry and Biomedicine , Innrain 80-82 , 6020 Innsbruck , Austria
2 shared publicationsRonald Gust
2 shared publicationsAndreas Bernkop-Schnürch
1 shared publication- Andreas Bernkop-Schnürch
Department of Pharmaceutical Technology Institute of Pharmacy University of Innsbruck Innsbruck Austria
1 shared publication
Latest Publications
- 1 August 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (17) , 8053-8061
A New Approach in Cancer Treatment: Discovery of Chlorido[N,N′-disalicylidene-1,2-phenylenediamine]iron(III) Complexes as Ferroptosis Inducers
Chlorido[N,N′-disalicylidene-1,2-phenylenediamine]iron(III) complexes generate lipid-based ROS and induce ferroptosis in leukemia and neuroblastoma cell lines. The extent of ferroptosis on the mode of action is regulated by simple modifications of the substituents at the 1,2-phenylenediamine moiety. In HL-60 cells, the unsubstituted lead exclusively caused ferroptosis. For instance, a 4-F substituent shifted the mode of action toward both ferroptosis and necroptosis, while the analogously chlorinated derivative exerted only necroptosis. Remarkably, cell-death in NB1 neuroblastoma cells was solely induced by ferroptosis, independent of the used substituents. The effects were higher than that of the therapeutically applied drug cisplatin. These data clearly demonstrate for the first time that not only iron ions but also iron salophene complexes are potent ferroptosis inducers, which can be optimized as antitumor agents.
- 1 August 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (17) , 8053-8061
A New Approach in Cancer Treatment: Discovery of Chlorido[N,N′-disalicylidene-1,2-phenylenediamine]iron(III) Complexes as Ferroptosis Inducers
Chlorido[N,N′-disalicylidene-1,2-phenylenediamine]iron(III) complexes generate lipid-based ROS and induce ferroptosis in leukemia and neuroblastoma cell lines. The extent of ferroptosis on the mode of action is regulated by simple modifications of the substituents at the 1,2-phenylenediamine moiety. In HL-60 cells, the unsubstituted lead exclusively caused ferroptosis. For instance, a 4-F substituent shifted the mode of action toward both ferroptosis and necroptosis, while the analogously chlorinated derivative exerted only necroptosis. Remarkably, cell-death in NB1 neuroblastoma cells was solely induced by ferroptosis, independent of the used substituents. The effects were higher than that of the therapeutically applied drug cisplatin. These data clearly demonstrate for the first time that not only iron ions but also iron salophene complexes are potent ferroptosis inducers, which can be optimized as antitumor agents.
- 1 August 2015
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 104 (8) , 2523-2530
Synthesis and In Vitro Evaluation of Thiolated Carrageenan
- 1 August 2015
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 104 (8) , 2523-2530
Synthesis and In Vitro Evaluation of Thiolated Carrageenan
- 1 May 2013
- Published by Elsevier in Acta Biomaterialia
- Vol. 9 (5) , 6585-6593
Thiopyrazole preactivated chitosan: Combining mucoadhesion and drug delivery
- 1 May 2013
- Published by Elsevier in Acta Biomaterialia
- Vol. 9 (5) , 6585-6593
Thiopyrazole preactivated chitosan: Combining mucoadhesion and drug delivery
- 7 December 2012
- Published by Wiley in Journal of Separation Science
- Vol. 35 (24) , 3434-3438
Development and validation of a LC method for the separation and determination of the anticancer‐active FeIII(4‐methoxy‐salophene) using the new second‐generation monolith
LC method with the newly introduced second‐generation monolithic silica RP‐18e column has been developed for the separation of FeIII(salophene) and four methoxy‐substituted FeIII(salophene) complexes. The method has been validated for the quantitation of FeIII(4‐OMe‐salophene), a highly active anticancer substance in vitro, bound to serum albumin. Our routinely used high‐resolution continuum‐source atomic absorption spectroscopy method based on the determination of the central iron atom was unsuitable in this case because serum originally contains significant amounts of iron as revealed by a blank sample of serum albumin. The developed LC method depends on detecting the whole complex rather than the bound iron. Two morphologically different first‐ and second‐generation HPLC monolithic columns have been compared for this purpose. The newly introduced second‐generation monolithic silica column Chromolith® HighResolution RP‐18e column (100 × 4.6 mm, Merck) separated the mixture successful within 13 min. A mobile phase consisting of 25 mM phosphate buffer pH 3/methanol (60:40, v/v) was used at a flow rate of 1 mL/min. The dynamic linear working range of the calibration curve for FeIII(4‐OMe‐salophene) was found to be between 1 and 200 μg/mL. Detection and quantitation limits were 0.3 and 1 μg/mL, respectively.
- 7 December 2012
- Published by Wiley in Journal of Separation Science
- Vol. 35 (24) , 3434-3438
Development and validation of a LC method for the separation and determination of the anticancer‐active FeIII(4‐methoxy‐salophene) using the new second‐generation monolith
LC method with the newly introduced second‐generation monolithic silica RP‐18e column has been developed for the separation of FeIII(salophene) and four methoxy‐substituted FeIII(salophene) complexes. The method has been validated for the quantitation of FeIII(4‐OMe‐salophene), a highly active anticancer substance in vitro, bound to serum albumin. Our routinely used high‐resolution continuum‐source atomic absorption spectroscopy method based on the determination of the central iron atom was unsuitable in this case because serum originally contains significant amounts of iron as revealed by a blank sample of serum albumin. The developed LC method depends on detecting the whole complex rather than the bound iron. Two morphologically different first‐ and second‐generation HPLC monolithic columns have been compared for this purpose. The newly introduced second‐generation monolithic silica column Chromolith® HighResolution RP‐18e column (100 × 4.6 mm, Merck) separated the mixture successful within 13 min. A mobile phase consisting of 25 mM phosphate buffer pH 3/methanol (60:40, v/v) was used at a flow rate of 1 mL/min. The dynamic linear working range of the calibration curve for FeIII(4‐OMe‐salophene) was found to be between 1 and 200 μg/mL. Detection and quantitation limits were 0.3 and 1 μg/mL, respectively.
- 1 March 2012
- Published by Elsevier in Microchemical Journal
- Vol. 101, 24-29
Determination of NiII(3-OMe-salophene) in MCF7 and HT29 cancer cell lines using HR-CS-AAS and in serum albumin using LC with monolithic silica
- 1 March 2012
- Published by Elsevier in Microchemical Journal
- Vol. 101, 24-29
Determination of NiII(3-OMe-salophene) in MCF7 and HT29 cancer cell lines using HR-CS-AAS and in serum albumin using LC with monolithic silica
- 1 September 2009
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 48 (9) , 575-584
Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline
Rapid emergence of resistance against antibacterial s emphasizes the need for the development of novel and/or more potent antibacterials. Tigecycline is the first representative of a new drug class, the glycylcyclines, and was approved in 2005 by the US FDA for the treatment of complicated skin and skin structure infections, as well as complicated intra-abdominal infections. Tigecycline distributes extensively into the intracellular space of tissue and accumulates in cells, which may qualify it for the treatment of intracellular infections. The pharmacokinetics of tigecycline are complex with both linear and non-linear characteristics. The reason for this complexity is still not fully understood. Non-linearity can be found in the volume of distribution possibly due to extensive and variable tissue and/or plasma protein binding. In contrast, clearance and area under the plasma concentration-time curve are dose-independent. Tigecycline has a high incidence of mild adverse effects, mainly nausea and vomiting, but is otherwise well tolerated.
- 1 September 2009
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 48 (9) , 575-584
Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline
Rapid emergence of resistance against antibacterial s emphasizes the need for the development of novel and/or more potent antibacterials. Tigecycline is the first representative of a new drug class, the glycylcyclines, and was approved in 2005 by the US FDA for the treatment of complicated skin and skin structure infections, as well as complicated intra-abdominal infections. Tigecycline distributes extensively into the intracellular space of tissue and accumulates in cells, which may qualify it for the treatment of intracellular infections. The pharmacokinetics of tigecycline are complex with both linear and non-linear characteristics. The reason for this complexity is still not fully understood. Non-linearity can be found in the volume of distribution possibly due to extensive and variable tissue and/or plasma protein binding. In contrast, clearance and area under the plasma concentration-time curve are dose-independent. Tigecycline has a high incidence of mild adverse effects, mainly nausea and vomiting, but is otherwise well tolerated.